
New data demonstrate that evolocumab (Repatha) significantly reduced low-density lipoprotein cholesterol and non-high density lipoprotein cholesterol in patients with type 2 diabetes plus hypercholesterolemia or mixed dyslipidemia.

New data demonstrate that evolocumab (Repatha) significantly reduced low-density lipoprotein cholesterol and non-high density lipoprotein cholesterol in patients with type 2 diabetes plus hypercholesterolemia or mixed dyslipidemia.

Newly published findings from the PIONEER 1 phase 3a trial show that once-daily once-daily oral semaglutide was associated with significant reductions in blood sugar in adults with type 2 diabetes.

In addition to showing no significant imbalance of BKLE amputation, the study also identified a HHF reduction in the general T2D population.

People with T2D have an increased risk of damage to the eyes, kidneys, nerves, legs, heart and brain, and many of these complications can ultimately affect mortality.

Risk factor modification remains key to managing patients with HIV and diabetes.

In this video, Priscilla Hsue, MD, from the University of California San Francisco School of Medicine, explains other health issues patietns with HIV may face as they age.

Kathryn Kreider, DNP, FNP-BC, BC-ADM, explains diabetes associations and the implications it has on health management for patients with diabetes.

Kathryn Kreider, DNP, FNP-BC, BC-ADM, from Duke University, discusses treatment options for patients with diabetes distress.

Leaders in diabetes research and treatment provide resources to overcome gendered disparities in the field.

A study of another such program—Healthy MOMs, or Mothers on the Move—has shown significant improvements in dietary practices and the incidence of depressive symptoms in Latina mothers at risk for type 2 diabetes.

The top prizes in the global Ascenia Diabetes Challenge were announced Friday at the American Diabetes Association’s 78th Annual Scientific Sessions in Orlando, Florida.

Patients with type 1 diabetes who received a generic vaccine had normal blood sugar levels 8 years later.

A look at last week's top stories in the world of pharmacy.

Senseonics was granted FDA approval for the Eversense Continuous Glucose Monitoring (CGM) system’s use in people 18 years of age and older with diabetes.

Officials with the FDA have expanded the approval of Medtronic’s MiniMed 670G hybrid closed looped system to include individuals aged 7 to 13 with Type 1 diabetes.

While normally a diabetes diagnosis requires multiple sample confirmations from blood work of elevated hemoglobin A1C (HbA1C) or glucose, new data has shown that a single-sample confirmatory diagnosis of diabetes may be possible.

Pharmacists have an important role in screening for behavioral health disorders in patients with high-risk conditions, including diabetes.

Adults with diabetes are 2 to 4 times more likely to have cardiovascular disease, which includes heart disease, heart failure, heart attack and stroke, than people without diabetes

Tracey D. Brown will welcome 16,000 attendees to the premier diabetes health care conference in her first month as chief executive of the American Diabetes Association.

The American Diabetes Association at its 78th Scientific Sessions will recognize 4 physicians who have worked to advance diabetes research and improve patient health outcomes.

At the American Pharmacy Purchasing Alliance's PharmCon, Michael Castagna, PharmD, MBA, and CEO of Mannkind Corporation discussed the need for a larger focus on patient outcomes in order to better address the diabetes pandemic occurring in the United States.

The Working Group examined the insulin supply chain and the factors that impact the costs of and access to insulin products.

At the American Pharmacy Purchasing Alliance’s PharmCon in Orlando, FL, experts with collaborative practice experience discussed why these pharmacist-physician partnerships are useful, and how they can effectively work.

Some 13,000 health care professionals from around the world convene each year at this popular meeting to discuss case studies, sympsia, oral presentations, and other forms of new research.

Half of people who have diabetes eventually develop diabetic peripheral neuropathy, and the warning signs are sensory symptoms that start in the distant periphery and progressing in a characteristic 'glove and stocking' way.